Pharmacy Home Adherence Reporting and Monitoring Outcomes Study
NCT02306122
Completed
This study is a pilot test of an intervention that delivers timely diagnostic information about medication nonadherence to doctors, and then offers the services of clinical pharmacists to treat these nonadherence problems. Participating doctors will be notified when a patient is 10 days late refilling a medication for diabetes, hypertension, or hypercholesterolemia. In one randomization arm the pharmacist will contact the patient as the default option (with no action required by the doctor), and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2021
Locations: Brown University, Providence, Rhode Island
Conditions: Diabetes, Hypertension, Hypercholesterolemia
Register for Updates
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
NCT02636036
Completed
This is a Phase I multicenter, open label, nonrandomized study of enadenotucirev administered in combination with nivolumab in subjects with metastatic or advanced epithelial tumors (with focus on CRC, SCCHN, escalation phase), not responding to standard therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2021
Locations: University of Arizona Cancer Center, 1515 North Campbell Ave., Tucson, Arizona +5 locations
Conditions: Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor
Register for Updates
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
NCT01392183
Completed
The goal of this clinical research study is to compare pazopanib to temsirolimus in the treatment of advanced clear-cell renal cell carcinoma. The safety of each drug will also be studied. Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for tumor growth. This may prevent or slow the growth of cancer cells. Temsirolimus is designed to block the growth of cancer cells, which may cause cancer cells to die. This is an investigational study. Pazopanib and te... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/24/2021
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Kidney Cancer
Register for Updates
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
NCT04267575
Unknown
The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction. Patients with stage 4 resectable tumors as decided by a multidisciplinary disease management team may be included if the metastatic disease is non-synchronous (e.g. recurrent colorectal carcinoma with hepatic metastasis amenable for surgical resection).. Plasma is an ionized gas typically generated... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2021
Locations: Canady Surgical Group PC, Washington, District of Columbia
Conditions: Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Fallopian Tube Cancer, Stage IV Colon Cancer, Stage IV Colorectal Cancer, Stage IV Liver Cancer, Stage IV Renal Cell Cancer, Stage IV Rectal Cancer, Stage IV Lung Cancer, Stage IV Small Intestinal Cancer, Stage IV Gastric Cancer, Stage IV Bladder Cancer
Register for Updates
Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects
NCT03401671
Completed
The purpose of this study is to evaluate the pharmacokinetics (PK), safety and tolerability and pharmacodynamics (PD) of lanadelumab in healthy adult Japanese subjects and matched non-Hispanic healthy adult Caucasian subjects.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/13/2021
Locations: WCCT Global, Inc., Cypress, California
Conditions: Healthy Volunteers
Register for Updates
ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
NCT04467931
Completed
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, enters type II pneumocytes using angiotensin-converting enzyme 2 (ACE2). It is unclear whether ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) increase, decrease, or have no significant effect on ACE2 expression or activity. Therefore, ACEI and ARB may be harmful, beneficial, or have no impact on Coronavirus Disease 2019 severity and mortality. The Specific Aims of this observational... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2021
Locations: University of Utah, Salt Lake City, Utah
Conditions: Hypertension, COVID
Register for Updates
LutrePulse Hypogonadotropic Hypogonadism
NCT01976728
Completed
To compare the ovulation rate in women with primary amenorrhea with hypogonadotropic hypogonadism following pulsatile gonadotropin-releasing hormone (GnRH) treatment using the OmniPod pump versus placebo
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
02/09/2021
Locations: Fertility Treatment Center, Tempe, Arizona +34 locations
Conditions: Primary Amenorrhea With Hypogonadotropic Hypogonadism
Register for Updates
Fexofenadine Use in Gastroesophageal Reflux Symptoms
NCT03425097
Terminated
The investigators wish to study the effectiveness of Fexofenadine (an over the counter allergy pill) for the treatment of gastroesophageal reflux symptoms in patients who still have symptoms despite being on a proton pump inhibitor. The investigators will do this by giving participants both Fexofenadine (an H1 blocker) for 2 weeks and placebo (sugar pill) for 2 weeks. The participants will not know which drug they are getting at a particular time. This will help the investigators better assess t... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/27/2021
Locations: Stanford Health Care, Redwood City, California
Conditions: Gastroesophageal Reflux
Register for Updates
Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations
NCT00700778
Terminated
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of recombinant human chorionic gonadotropin may prevent breast cancer in premenopausal women with BRCA1 mutations. PURPOSE: This clinical trial is studying recombinant human chorionic gonadotropin in preventing breast cancer in premenopausal women with BRCA1 mutations.
Gender:
FEMALE
Ages:
Between 20 years and 40 years
Trial Updated:
01/04/2021
Locations: Mayo Clinic Cancer Center, Rochester, Minnesota +2 locations
Conditions: BRCA1 Mutation, Breast Cancer
Register for Updates
Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash
NCT00656786
Completed
This is a clinical research study of an experimental new medication, Menadione Topical Lotion (MTL). The study lotion is experimental and has not been approved for public use. Hana Biosciences, Inc., the company that is developing MTL, is the sponsor of this study. EGFR inhibitors are used to treat non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, breast cancer and head and neck cancer. One of the side effects of EFGR inhibitors is skin toxicities including an acneform sk... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2020
Locations: Solano Clinical Research, Vallejo, California +6 locations
Conditions: EGFR Inhibitor-associated Rash
Register for Updates
Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia
NCT04460105
Withdrawn
The purpose of this study is to evaluate the safety, pharmacokinetic and pharmacodynamics of lanadelumab administered by intravenous (IV) infusion when added to standard-of-care (SoC) in adults hospitalized with COVID-19 pneumonia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2020
Locations: Cardiology Associates Research Company, Daytona Beach, Florida +1 locations
Conditions: COVID-19 Pneumonia
Register for Updates
Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
NCT02045277
Completed
The objective of the study is to evaluate the safety and efficacy of a topical lotion
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2020
Locations: Valeant Site 13, Encino, California +17 locations
Conditions: Plaque Psoriasis
Register for Updates